ReviewEuropean journal of pediatrics1993
Glucose-6-phosphatase and type 1 glycogen storage disease: some critical considerations.
Review in European journal of pediatrics, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 13 citations in OpenAlex.
- A novel analytical method for in vivo phosphate tracking.FEBS letters · 2006Article
- Identification of protein components of the microsomal glucose 6-phosphate transporter by photoaffinity labelling.The Biochemical journal · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There now is compelling evidence that hydrolysis of glucose-6-phosphate (Glc-6-P) in intact hepatic endoplasmic reticulum (ER) membrane preparations involves four integral components of the membrane: a Glc-6-P specific transporter (T1), a nonspecific enzyme (E) with its active site facing the lumen, and two other transport systems to mediate rapid and reversible fluxes of the hydrolytic products, inorganic phosphate (Pi) and glucose, i.e. (T2) and (T3), respectively. T2 also mediates transport of inorganic pyrophosphate (PPi) and carbamylphosphate. This concept readily and completely reconciles all known characteristics of the glucose-6-phosphatase (Glc-6-P'ase) system provided appropriate considerations are given to: (1) the quantitative contribution of E residing in membranes lacking a permeability barrier; (2) the kinetic restrictions imposed by T1 and T2; and (3) the influences of the endocrine, developmental and nutritional state on the kinetic relationship between the capacities to transport and hydrolyze. A broader-based understanding and application of these principles in the study of Glc-6-P'ase is needed to ensure accurate diagnosis of type 1 glycogen storage disease (GSD) and minimize unnecessary controversy. The view that the enzyme in native ER membranes is conformationally constrained is not supported by direct measurements of the catalytic turnover number. Finally, we describe the marked deficiencies of rapid filtration assays of Glc-6-P and PPi "uptake" as a direct method of diagnosis of types 1b and 1c GSD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.